These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22802008)

  • 1. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
    Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
    Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
    Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
    Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
    Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
    Verburg FA; Hänscheid H; Biko J; Hategan MC; Lassmann M; Kreissl MC; Reiners C; Luster M
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):896-903. PubMed ID: 20033685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
    Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
    Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I.
    Jentzen W; Bockisch A; Ruhlmann M
    J Nucl Med; 2015 Jun; 56(6):832-8. PubMed ID: 25858042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
    Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry in differentiated thyroid carcinoma (12-1402R).
    Minguez P; Genolla J; Celeiro JJ; Fombellida JC
    Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
    Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
    Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
    J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
    Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
    Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
    Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
    J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in the blood picture after radioiodine therapy of thyroid cancer].
    Grünwald F; Schomburg A; Menzel C; Steinecker S; Späth G; Bockisch A; Fimmers R; Hotze AL; Biersack HJ
    Med Klin (Munich); 1994 Oct; 89(10):522-8. PubMed ID: 7808352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.